Author

Astraea Jager

Stanford Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:statistical model· 1

Frequent Co-Authors

Charles Grenfell MullighaniD· 2 shared Jolanda SarnoiD· 2 shared Kara Lynn DavisiD· 2 shared Milton J. Merchant· 2 shared Pablo DomiziiD· 2 shared Sean C. BendalliD· 2 shared Yuxuan LiuiD· 2 shared Abhishek KoladiyaiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Charles Grenfell MullighanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia

Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton J. Merchant, Kaithlen Zen Pacheco, Sean A. Yamada‐Hunter, Maria Caterina Rotiroti, Yuxuan Liu, Reema Baskar, Warren D. Reynolds, Brian J. Sworder, Bita Sahaf, Sean C. Bendall, Charles Grenfell Mullighan, Ash A. Alizadeh, , Kara Lynn Davis

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

Nature Communications · Apr 23, 2025Peer-reviewedCancer Biology

Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL

Yuxuan Liu, Haowen Jiang, Jingjing Liu, Lucille Stuani, Milton J. Merchant, Astraea Jager, Abhishek Koladiya, Ti‐Cheng Chang, Pablo Domizi, Jolanda Sarno, Timothy Keyes, Dorra Jedoui, Ao Wang, Jodie Meng, Felix J. Hartmann, , Kara Lynn Davis

This study identifies uridine metabolism as a therapeutic target for chemo-resistant B-ALL by linking active signaling to uridine dependency and demonstrating DHODH inhibition as a promising treatment.

bioRxiv · Jan 27, 2025 · PreprintCancer Biology